{"title": "PDF", "author": "PDF", "url": "https://scholar.archive.org/work/fpgm2ocn3rfmrbddn7i75mf5cy/access/wayback/http://www.dtic.mil/dtic/tr/fulltext/u2/a513361.pdf", "hostname": "PDF", "description": "PDF", "sitename": "PDF", "date": "PDF", "cleaned_text": "Approved for public release. Distribution is unlimited.Infectious Disorders OMB No. 0704-0188 Public reporting burden for the collection of information is estimated to average 1 hour per response, including the time for r eviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden es timate or any other aspect of this collection of information, including suggestions for reducing this burden, to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to a pen alty for failing to comply with a collection of information if it does not display a currently valid OMB control number. 1. REPORT DATE 23 OCT 2009 2. REPORT TYPE N/A 3. DATES COVERED - 4. TITLE AND SUBTITLE Drug targets in infections with Ebola and Marburg viruses. InfectiousDisorders - Drug Targets 9:191-200 5a. CONTRACT NUMBER 7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) United States Army Medical Research Institute of Infectious Diseases,Fort Detrick, MD 8. PERFORMING ORGANIZATION REPORT NUMBER SPONSOR/MONITOR'S REPORT NUMBER(S) 12. DISTRIBUTION/AVAILABILITY STATEMENT Approved for public release, distribution unlimited 13. SUPPLEMENTARY NOTES 14. ABSTRACT The development of antiviral drugs for Ebola and Marburg viruses has been slow. To date, beyondsupportive care, no effective treatments, prophylactic measures, therapies or vaccines are approved totreat or prevent filovirus infections. In this review, we examine the current treatments available toadminister care for filovirus infection, the potential therapeutic targets that can be used for filovirus drugdevelopment, and the various drug targeting techniques used against filoviruses. 15. SUBJECT TERMS filovirus, Ebola, Marburg, drug targets, antivirals, drug development 16. SECURITY CLASSIFICATION OF: 17. LIMITATION OF ABSTRACT SAR 18. NUMBER OF PAGES 9 19a. NAME OF RESPONSIBLE PERSON a. REPORT unclassified b. ABSTRACT unclassified c. THIS PAGE unclassified Standard Form 298 (Rev. 8-98) Prescribed by ANSI Std Z39-18 Approved for public DEVELOPMENTS supportive Disorders -DrugTargets2009,VoL9,No.1 Postexposure vaccination isalsobeingevaluated asa POTENTIAL "}